Recent Advances on the Role of G Protein-Coupled Receptors in Hypoxia-Mediated Signaling

详细信息    查看全文

• 作者：Rosamaria Lappano ; Damiano Rigiracciolo ; Paola De Marco ; Silvia Avino…
• 关键词：angiogenesis ; GPCRs ; GPER ; hypoxia ; signal transduction
• 刊名：The AAPS Journal
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：18
• 期：2
• 页码：305-310
• 全文大小：317 KB
• 参考文献：1.Rosenbaum DM, Rasmussen SG, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature. 2009;459:356–63.CrossRef PubMed PubMedCentral
  2.Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol. 2002;3:639–50.CrossRef PubMed
  3.Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer. 2007;7:79–94.CrossRef PubMed
  4.Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov. 2011;10:47–60.CrossRef PubMed
  5.Maggiolini M, Picard D. The unfolding stories of GPR30, a new membrane-bound estrogen receptor. J Endocrinol. 2010;204:105–14.CrossRef PubMed
  6.Lappano R, Pisano A, Maggiolini M. GPER function in breast cancer: an overview. Front Endocrinol (Lausanne). 2014;5:66.
  7.Albanito L, Lappano R, Madeo A, Chimento A, Prossnitz ER, Cappello AR, et al. Effects of atrazine on estrogen receptor α- and G protein-coupled receptor 30-mediated signaling and proliferation in cancer cells and cancer-associated fibroblasts. Environ Health Perspect. 2015;5:493–9.
  8.Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V, et al. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem. 2004;279:27008–16.CrossRef PubMed
  9.Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M, Picard D. Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J. 2009;28:523–32.CrossRef PubMed PubMedCentral
  10.Pupo M, Pisano A, Lappano R, Santolla MF, De Francesco EM, Abonante S, et al. Bisphenol A induces gene expression changes and proliferative effects through GPER in breast cancer cells and cancer-associated fibroblasts. Environ Health Perspect. 2012;120:1177–82.CrossRef PubMed PubMedCentral
  11.Madeo A, Maggiolini M. Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts. Cancer Res. 2010;70:6036–46.CrossRef PubMed
  12.Lappano R, Rosano C, De Marco P, De Francesco EM, Pezzi V, Maggiolini M. Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. Mol Cell Endocrinol. 2010;320:162–70.CrossRef PubMed
  13.Ariazi EA, Brailoiu E, Yerrum S, Shupp HA, Slifker MJ, Cunliffe HE, et al. The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res. 2010;70:1184–94.CrossRef PubMed PubMedCentral
  14.Wei W, Chen ZJ, Zhang KS, Yang XL, Wu YM, Chen XH, et al. The activation of G protein-coupled receptor 30 (GPR30) inhibits proliferation of estrogen receptor-negative breast cancer cells in vitro and in vivo. Cell Death Dis. 2014;5, e1428.CrossRef PubMed PubMedCentral
  15.Weißenborn C, Ignatov T, Ochel HJ, Costa SD, Zenclussen AC, Ignatova Z, et al. GPER functions as a tumor suppressor in triple-negative breast cancer cells. J Cancer Res Clin Oncol. 2014;140:713–23.CrossRef PubMed
  16.Weißenborn C, Ignatov T, Poehlmann A, Wege AK, Costa SD, Zenclussen AC, et al. GPER functions as a tumor suppressor in MCF-7 and SK-BR-3 breast cancer cells. J Cancer Res Clin Oncol. 2014;140:663–71.CrossRef PubMed
  17.Marjon NA, Hu C, Hathaway HJ, Prossnitz ER. G protein-coupled estrogen receptor regulates mammary tumorigenesis and metastasis. Mol Cancer Res. 2014;12:1644–54.CrossRef PubMed PubMedCentral
  18.Arias-Pulido H, Royce M, Gong Y, Joste N, Lomo L, Lee SJ, et al. GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer. Breast Cancer Res Treat. 2010;123:51–8.CrossRef PubMed PubMedCentral
  19.Ignatov T, Weißenborn C, Poehlmann A, Lemke A, Semczuk A, Roessner A, et al. GPER-1 expression decreases during breast cancer tumorigenesis. Cancer Invest. 2013;31:309–15.CrossRef PubMed
  20.Ignatov A, Ignatov T, Weissenborn C, Eggemann H, Bischoff J, Semczuk A, et al. G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. Breast Cancer Res Treat. 2011;128:457–66.CrossRef PubMed
  21.Sjöström M, Hartman L, Grabau D, Fornander T, Malmström P, Nordenskjöld B, et al. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer. Breast Cancer Res Treat. 2014;145:61–71.CrossRef PubMed
  22.Smith HO, Leslie KK, Singh M, Qualls CR, Revankar CM, Joste NE, et al. GPR30: a novel indicator of poor survival for endometrial carcinoma. Am J Obstet Gynecol. 2007;196:386. e1-11.PubMed
  23.Smith HO, Arias-Pulido H, Kuo DY, Howard T, Qualls CR, Lee SJ, et al. GPR30 predicts poor survival for ovarian cancer. Gynecol Oncol. 2009;114:465–71.CrossRef PubMed PubMedCentral
  24.Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, et al. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res. 2006;12:6359–66.CrossRef PubMed
  25.Albanito L, Sisci D, Aquila S, Brunelli E, Vivacqua A, Madeo A, et al. Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells. Endocrinology. 2008;149:3799–808.CrossRef PubMed PubMedCentral
  26.Vivacqua A, Lappano R, De Marco P, Sisci D, Aquila S, De Amicis F, et al. G protein-coupled receptor 30 expression is up-regulated by EGF and TGF alpha in estrogen receptor alpha-positive cancer cells. Mol Endocrinol. 2009;23:1815–26.CrossRef PubMed
  27.Bartella V, De Marco P, Malaguarnera R, Belfiore A, Maggiolini M. New advances on the functional cross-talk between insulin-like growth factor-I and estrogen signalling in cancer. Cell Signal. 2012;24:1515–21.CrossRef PubMed
  28.De Marco P, Bartella V, Vivacqua A, Lappano R, Santolla MF, Morcavallo A, et al. Insulin-like growth factor-I regulates GPER expression and function in cancer cells. Oncogene. 2013;32:678–88.CrossRef PubMed
  29.De Marco P, Romeo E, Vivacqua A, Malaguarnera R, Abonante S, Romeo F, et al. GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts. Endocr Relat Cancer. 2014;21:739–53.CrossRef PubMed
  30.Recchia AG, De Francesco EM, Vivacqua A, Sisci D, Panno ML, Andò S, et al. The G protein-coupled receptor 30 is up-regulated by hypoxia-inducible factor-1alpha (HIF-1alpha) in breast cancer cells and cardiomyocytes. J Biol Chem. 2011;286:10773–82.CrossRef PubMed PubMedCentral
  31.De Francesco EM, Lappano R, Santolla MF, Marsico S, Caruso A, Maggiolini M. HIF-1α/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs). Breast Cancer Res. 2013;15:R64.CrossRef PubMed PubMedCentral
  32.Harris AL. Hypoxia—a key regulator factor in tumor growth. Nat Rev Cancer. 2002;2:38–47.CrossRef PubMed
  33.Bishop T, Ratcliffe PJ. HIF hydroxylase pathways in cardiovascular physiology and medicine. Circ Res. 2015;117:65–79.CrossRef PubMed PubMedCentral
  34.Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012;33:207–14.CrossRef PubMed PubMedCentral
  35.Manalo DJ, Rowan A, Lavoie T, Natarajan L, Kelly BD, Ye SQ, et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood. 2005;105:659–69.CrossRef PubMed
  36.Glück AA, Aebersold DM, Zimmer Y, Medová M. Interplay between receptor tyrosine kinases and hypoxia signaling in cancer. Int J Biochem Cell Biol. 2015;62:101–14.CrossRef PubMed
  37.Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A. 1993;90:4304–8.CrossRef PubMed PubMedCentral
  38.Semenza GL, Aganì F, Booth G, Forsythe J, Iyer N, Jiang H, et al. Structural and functional analysis of hypoxia-inducible factor I. Kidney Int. 1997;51:553–5.CrossRef PubMed
  39.Guo M, Cai C, Zhao G, Qiu X, Zhao H, Ma Q, et al. Hypoxia promotes migration and induces CXCR4 expression via HIF-1α activation in human osteosarcoma. PLoS One. 2014;9, e90518.CrossRef PubMed PubMedCentral
  40.Kimura M, Mizukami Y, Miura T, Fujimoto K, Kobayashi S, Matsuzaki M. Orphan G protein-coupled receptor, GPR41, induces apoptosis via a p53/Bax pathway during ischemic hypoxia and reoxygenation. J Biol Chem. 2001;276:26453–60.CrossRef PubMed
  41.Adams JW, Wang J, Davis JR, Liaw C, Gaidarov I, Gatlin J, et al. Myocardial expression, signaling, and function of GPR22: a protective role for an orphan G protein-coupled receptor. Am J Physiol Heart Circ Physiol. 2008;295:H509–21.CrossRef PubMed
  42.Corbi G, Conti V, Russomanno G, Longobardi G, Furgi G, Filippelli A, et al. Adrenergic signaling and oxidative stress: a role for sirtuins? Front Physiol. 2013;4:324.CrossRef PubMed PubMedCentral
  43.Jordan BA, Gomes I, Rios C, Filipovska J, Devi LA. Functional interactions between mu opioid and alpha 2A-adrenergic receptors. Mol Pharmacol. 2003;64:1317–24.CrossRef PubMed
  44.Headrick JP, See Hoe LE, Du Toit EF, Peart JN. Opioid receptors and cardioprotection-opioidergic conditioning’ of the heart. Br J Pharmacol. 2015;172:2026–50.CrossRef PubMed
  45.Gao CJ, Niu L, Ren PC, Wang W, Zhu C, Li YQ, et al. Hypoxic preconditioning attenuates global cerebral ischemic injury following asphyxial cardiac arrest through regulation of delta opioid receptor system. Neuroscience. 2012;202:352–62.CrossRef PubMed
  46.Caprara V, Scappa S, Garrafa E, Di Castro V, Rosanò L, Bagnato A, et al. Endothelin-1 regulates hypoxia-inducible factor-1α and -2α stability through prolyl hydroxylase domain 2 inhibition in human lymphatic endothelial cells. Life Sci. 2014;118:185–90.CrossRef PubMed
  47.Hu HT, Ma QY, Zhang D, Shen SG, Han L, Ma YD, et al. HIF-1alpha links beta-adrenoceptor agonists and pancreatic cancer cells under normoxic condition. Acta Pharmacol Sin. 2010;31:102–10.CrossRef PubMed PubMedCentral
  48.Lee SJ, No YR, Dang DT, Dang LH, Yang VW, Shim H, et al. Regulation of hypoxia-inducible factor 1α (HIF-1α) by lysophosphatidic acid is dependent on interplay between p53 and Krüppel-like factor 5. J Biol Chem. 2013;288:25244–53.CrossRef PubMed PubMedCentral
  49.Baeriswyl V, Christofori G. The angiogenic switch in carcinogenesis. Semin Cancer Biol. 2009;19:329–37.CrossRef PubMed
  50.Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:66–76.
  51.Richard DE, Vouret-Craviari V, Pouyssegur J. Angiogenesis and G-protein-coupled receptors: signals that bridge the gap. Oncogene. 2001;20:1556–62.CrossRef PubMed
  52.Sumida H, Noguchi K, Kihara Y, Abe M, Yanagida K, Hamano F, et al. LPA4 regulates blood and lymphatic vessel formation during mouse embryogenesis. Blood. 2010;116:5060–70.CrossRef PubMed
  53.Moore BB, Keane MP, Addison CL, Arenberg DA, Strieter RM. CXC chemokine modulation of angiogenesis: the importance of balance between angiogenic and angiostatic members of the family. J Investig Med. 1998;46:113–20.PubMed
  54.Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest. 2000;106:951–61.CrossRef PubMed PubMedCentral
  55.Zeng H, Zhao D, Yang S, Datta K, Mukhopadhyay D. Heterotrimeric Gαq/Gα11 proteins function upstream of vascular endothelial growth factor (VEGF) receptor-2 (KDR) phosphorylation in vascular permeability factor/VEGF signaling. J Biol Chem. 2003;278:20738–45.CrossRef PubMed
  56.Rivas V, Carmona R, Muñoz-Chápuli R, Mendiola M, Nogués L, Reglero C, et al. Developmental and tumoral vascularization is regulated by G protein-coupled receptor kinase 2. P J Clin Invest. 2013;123:4714–30.CrossRef
  57.Sarvaiya PJ, Guo D, Ulasov I, Gabikian P, Lesniak MS. Chemokines in tumor progression and metastasis. Oncotarget. 2013;4:2171–85.CrossRef PubMed PubMedCentral
  58.Guha S, Eibl G, Kisfalvi K, Fan RS, Burdick M, Reber H, et al. Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1, D-Trp5,7,9, Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res. 2005;65:2738–45.CrossRef PubMed
  59.Jin F, Brockmeier U, Otterbach F, Metzen E. New insight into the SDF-1/CXCR4 axis in a breast carcinoma model: hypoxia-induced endothelial SDF-1 and tumor cell CXCR4 are required for tumor cell intravasation. Mol Cancer Res. 2012;10:1021–31.CrossRef PubMed
  60.Nikitenko LL, Leek R, Henderson S, Pillay N, Turley H, Generali D, et al. The G-protein-coupled receptor CRLR is upregulated in an autocrine loop with adrenomedullin in clear cell renal cell carcinoma and associated with poor prognosis. Clin Cancer Res. 2013;19:5740–8.CrossRef PubMed
  61.Nikitenko LL, Smith DM, Bicknell R, Rees MC. Transcriptional regulation of the CRLR gene in human microvascular endothelial cells by hypoxia. FASEB J. 2003;17:1499–501.PubMed
  62.Yamashita K, Discher DJ, Hu J, Bishopric NH, Webster KA. Molecular regulation of the endothelin-1 gene by hypoxia. Contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, AND p300/CBP. J Biol Chem. 2001;276:12645–53.CrossRef PubMed
  63.Wu MH, Huang CY, Lin JA, Wang SW, Peng CY, Cheng HC, et al. Endothelin-1 promotes vascular endothelial growth factor-dependent angiogenesis in human chondrosarcoma cells. Oncogene. 2014;33:1725–35.CrossRef PubMed
  64.Spinella F, Rosanò L, Di Castro V, Natali PG, Bagnato A. Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells. J Biol Chem. 2002;277:27850–5.CrossRef PubMed
  65.Bartella V, De Francesco EM, Perri MG, Curcio R, Dolce V, Maggiolini M, et al. The G protein estrogen receptor (GPER) is regulated by endothelin-1 mediated signaling in cancer cells. Cell Signal. 2016;2:61–71.CrossRef
  66.Moretti S, Massi D, Farini V, Baroni G, Parri M, Innocenti S, et al. β-Adrenoceptors are upregulated in human melanoma and their activation releases pro-tumorigenic cytokines and metalloproteases in melanoma cell lines. Lab Invest. 2013;279.
  67.Yang EV, Kim SJ, Donovan EL, Chen M, Gross AC, Webster Marketon JI, et al. Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behav Immun. 2009;23:267–75.CrossRef PubMed PubMedCentral
  68.Shan T, Ma J, Ma Q, Guo K, Guo J, Li X, et al. β2-AR-HIF-1α: a novel regulatory axis for stress-induced pancreatic tumor growth and angiogenesis. Curr Mol Med. 2013;13:1023–34.CrossRef PubMed PubMedCentral
  69.Dal Monte M, Casini G, Filippi L, Nicchia GP, Svelto M, Bagnoli P. Functional involvement of β3-adrenergic receptors in melanoma growth and vascularization. J Mol Med (Berl). 2013;91:1407–19.CrossRef
  70.Park MS, Kim BR, Dong SM, Lee SH, Kim DY, Rho SB. The antihypertension drug doxazosin inhibits tumor growth and angiogenesis by decreasing VEGFR-2/Akt/mTOR signaling and VEGF and HIF-1α expression. Oncotarget. 2014;5:4935–44.CrossRef PubMed PubMedCentral
  71.Ma T, Jham BC, Hu J, Friedman ER, Basile JR, Molinolo A, et al. Viral G protein-coupled receptor up-regulates angiopoietin-like 4 promoting angiogenesis and vascular permeability in Kaposi’s sarcoma. Proc Natl Acad Sci U S A. 2010;107:14363–8.CrossRef PubMed PubMedCentral
  72.Sodhi A, Montaner S, Patel V, Zohar M, Bais C, Mesri EA, et al. The Kaposi’s sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res. 2000;60:4873–80.PubMed
  73.Bais C, Van Geelen A, Eroles P, Mutlu A, Chiozzini C, Dias S, et al. Kaposi’s sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR. Cancer Cell. 2003;3:131–43.CrossRef PubMed
  74.De Francesco EM, Angelone T, Pasqua T, Pupo M, Cerra MC, Maggiolini M. GPER mediates cardiotropic effects in spontaneously hypertensive rat hearts. PLoS One. 2013;8, e69322.CrossRef PubMed PubMedCentral
  75.Patel VH, Chen J, Ramanjaneya M, Karteris E, Zachariades E, Thomas P, et al. G-protein coupled estrogen receptor 1 expression in rat and human heart: protective role during ischaemic stress. Int J Mol Med. 2010;26:193–9.PubMed
  76.Meyer MR, Prossnitz ER, Barton M. The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function. Vascul Pharmacol. 2011;55:17–25.CrossRef PubMed PubMedCentral
  77.Deschamps AM, Murphy E, Sun J. Estrogen receptor activation and cardioprotection in ischemia reperfusion injury. Trends Cardiovasc Med. 2011;20:73–8.CrossRef
  78.Deschamps AM, Murphy E. Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats. Am J Physiol Heart Circ Physiol. 2009;297:H1806–13.CrossRef PubMed PubMedCentral
  79.Weil BR, Manukyan MC, Herrmann JL, Wang Y, Abarbanell AM, Poynter JA, et al. Signaling via GPR30 protects the myocardium from ischemia/reperfusion injury. Surgery. 2010;148:436–43.CrossRef PubMed
  80.Zhang B, Subramanian S, Dziennis S, Jia J, Uchida M, Akiyoshi K, et al. Estradiol and G1 reduce infarct size and improve immunosuppression after experimental stroke. J Immunol. 2010;18:4087–94.CrossRef
  81.Li WL, Xiang W, Ping Y. Activation of novel estrogen receptor GPER results in inhibition of cardiocyte apoptosis and cardioprotection. Mol Med Rep. 2015;12:2425–30.PubMed PubMedCentral
  82.Czibik G. Complex role of the HIF system in cardiovascular biology. J Mol Med (Berl). 2010;88:1101–1.CrossRef
  83.Lindsey SH, Cohen JA, Brosnihan KB, Gallagher PE, Chappell MC. Chronic treatment with the G protein-coupled receptor 30 agonist G-1 decreases blood pressure in ovariectomized mRen2.Lewis rats. Endocrinology. 2009;150:3753–8.CrossRef PubMed PubMedCentral
  84.Meyer MR, Prossnitz ER, Barton M. GPER/GPR30 and regulation of vascular tone and blood pressure. Immunol, Endocr Metab Agents Med Chem. 2011;11:255–61.CrossRef
  85.Brailoiu E, Dun SL, Brailoiu GC, Mizuo K, Sklar LA, Oprea TI, et al. Distribution and characterization of estrogen receptor G protein-coupled receptor 30 in the rat central nervous system. J Endocrinol. 2007;193:311–21.CrossRef PubMed
  86.Chen J, Hu R, Ge H, Duanmu W, Li Y, Xue X, et al. G-protein-coupled receptor 30-mediated antiapoptotic effect of estrogen on spinal motor neurons following injury and its underlying mechanisms. Mol Med Rep. 2015;12:1733–40.PubMed PubMedCentral
  87.Murata T, Dietrich HH, Xiang C, Dacey Jr RG. G protein-coupled estrogen receptor agonist improves cerebral microvascular function after hypoxia/reoxygenation injury in male and female rats. Stroke. 2013;44:779–85.CrossRef PubMed PubMedCentral
  88.Broughton BR, Brait VH, Guida E, Lee S, Arumugam TV, Gardiner-Mann CV, et al. Stroke increases G protein-coupled estrogen receptor expression in the brain of male but not female mice. Neurosignals. 2013;21:229–39.CrossRef PubMed
  89.De Francesco EM, Pellegrino M, Santolla MF, Lappano R, Ricchio E, Abonante S, et al. GPER mediates activation of HIF1α/VEGF signaling by estrogens. Cancer Res. 2014;74:4053–64.CrossRef PubMed
  90.Rigiracciolo DC, Scarpelli A, Lappano R, Pisano A, Santolla MF, De Marco P, et al. Copper activates HIF-1α/GPER/VEGF signalling in cancer cells. Oncotarget. 2015;33:34158–77.
  91.Brewer GJ. Anticopper therapy against cancer and diseases of inflammation and fibrosis. Drug Discov Today. 2005;10:1103–19.CrossRef PubMed
  92.Rigiracciolo DC, Scarpelli A, Lappano R, Pisano A, Santolla MF, Avino S, et al. GPER is involved in the stimulatory effects of aldosterone in breast cancer cells and breast tumor-derived endothelial cells. Oncotarget. 2015 Dec 5. doi: 10.18632/oncotarget.6475.
  93.Tropea T, De Francesco EM, Rigiracciolo D, Maggiolini M, Wareing M, Osol G, et al. Pregnancy augments G protein estrogen receptor (GPER) induced vasodilation in rat uterine arteries via the nitric oxide—cGMP signaling pathway. PLoS One. 2015;10(11), e0141997.CrossRef PubMed PubMedCentral
  94.Xia Y, Choi HK, Lee K. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem. 2012;49:24–40.CrossRef PubMed
  
• 作者单位：Rosamaria Lappano (1)
  Damiano Rigiracciolo (1)
  Paola De Marco (1)
  Silvia Avino (1)
  Anna Rita Cappello (1)
  Camillo Rosano (2)
  Marcello Maggiolini (1)
  Ernestina Marianna De Francesco (1)
  
  1. Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Via Bucci, 87036, Rende, CS, Italy
  2. UOS Proteomics IRCCS AOU San Martino-IST National Institute for Cancer Research, Largo R. Benzi 10, 16132, Genoa, Italy
  
• 刊物主题：Pharmacology/Toxicology; Biochemistry, general; Biotechnology; Pharmacy;
• 出版者：Springer US
• ISSN：1550-7416

文摘

G protein-coupled receptors (GPCRs) are cell surface proteins mainly involved in signal transmission; however, they play a role also in several pathophysiological conditions. Chemically heterogeneous molecules like peptides, hormones, lipids, and neurotransmitters activate second messengers and induce several biological responses by binding to these seven transmembrane receptors, which are coupled to heterotrimeric G proteins. Recently, additional molecular mechanisms have been involved in GPCR-mediated signaling, leading to an intricate network of transduction pathways. In this regard, it should be mentioned that diverse GPCR family members contribute to the adaptive cell responses to low oxygen tension, which is a distinguishing feature of several illnesses like neoplastic and cardiovascular diseases. For instance, the G protein estrogen receptor, namely G protein estrogen receptor (GPER)/GPR30, has been shown to contribute to relevant biological effects induced by hypoxia via the hypoxia-inducible factor (HIF)-1α in diverse cell contexts, including cancer. Likewise, GPER has been found to modulate the biological outcome of hypoxic/ischemic stress in both cardiovascular and central nervous systems. Here, we describe the role exerted by GPCR-mediated signaling in low oxygen conditions, discussing, in particular, the involvement of GPER by a hypoxic microenvironment.